Defibrillators Lower Heart Failure Death Rate
Medicare Poised to Expand Coverage of Implantable Defibrillators to 500,000 People
WebMD News Archive
Jan. 19, 2005 -- Patients with mild to moderate heart failure survive longer with an
than by taking a common drug for irregular heartbeats.
The research that confirms the effectiveness of implantable defibrillators over the drug amiodarone for preventing sudden cardiac death is prompting federal officials to expand coverage for the devices to more than half a million at-risk patients.
That is two to three times the number of Medicare beneficiaries who are currently eligible for the implantable cardioverter-defibrillators (ICDs), FDA Commissioner Mark B. McClellan, MD, PhD, announced Wednesday.
In a statement published along with the study, McClellan notes that most patients with serious heart failure would qualify for the devices.
"We expect to finalize this decision within days, after synthesizing public comments and the final published evidence," McClellan writes.
Too Few Patients Get ICDs
Sudden cardiac death remains a leading cause of death among people who have had heart attacks and/or have heart failure.
In heart failure, the heart can no longer pump enough blood to meet the body's needs. Patients with the condition can die suddenly from arrhythmias -- irregular heartbeats. Treatment options to prevent these life-threatening events include medications such as amiodarone and implantable defibrillators.
The ICD is programmed to detect irregular heartbeats and give an electric shock when needed to reestablish normal rhythms.
Vice President Dick Cheney, who has a history of heart disease, became the world's most famous ICD recipient when he had the device implanted almost four years ago. But despite growing evidence of the lifesaving benefits of implantable defibrillators, only about 20% to 25% of patients who could potentially benefit from the devices are getting them, experts say.
A widely publicized study reported two years ago established the usefulness of ICDs among patients who had survived heart attacks. The risk of sudden death was reduced by 31% among survivors who got the devices compared with those who did not.
In the newly reported trial, published in the Jan. 20 issue of The New England Journal of Medicine, researchers evaluated the effectiveness of the ICD in patients with heart failure. Roughly 2,500 patients were enrolled in the trial.
Patients treated with conventional drug therapy for heart failure who also got an ICD were 23% less likely to die of sudden cardiac arrest than patients treated with conventional therapy plus amiodarone. The researchers concluded that the anti-arrhythmia drug did not improve long-term survival while the defibrillator did.